rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer

rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07662278 by Sichuan Huiyang Life Science and Technology Corporation, with a registry enrolment figure of 90 participants, started 2027-01 and due to reach its primary completion in 2030-01. Interventions recorded: Recombinant Super-Compound Interferon (rSIFN-co); Total Neo-adjuvant therapy. Conditions listed: Mid-low Locally Advanced Rectal Cancer. Primary outcome: To evaluate the complete response rate at the end of treatment period. Colorectal eligibility wording from the registry: "Subjects with histologically or cytologically confirmed mid-low locally advanced rectal cancer, with tumor location within 12 cm from the anal verge, as per UICC classification, and who are scheduled to undergo TNT in the opinion of the investigator 3". No results are recorded here; the registry entry is the source.